BioSpace News Archive

Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI ® .

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that preclinical and clinical data, including new clinical efficacy and safety data from the expansion cohorts in the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome, will be presented at the 76th Annual American Academy of Neurology Meeting (AAN) being held April 13-18 in Denver and virtually.

Praxis Precision Medicines, Inc. today announced that it will deliver presentations of two abstracts showcasing progress of its clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place in Denver, Colorado, April 13 – 18, 2024.

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens.

CND Life Sciences today announced that six abstracts related to the identification of phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers in the skin will be presented at the American Academy of Neurology 2024 Annual Meeting (AAN) on April 13-18 in Denver at the Colorado Convention Center.

Kyowa Kirin, Inc. will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the safety of NOURIANZ® (istradefylline) in relation to other levodopa adjunctive therapies for patients with Parkinson’s Disease (PD).

Sunshine Biopharma, Inc. announced today a one for one hundred reverse split of its common stock, effective at market open on April 17, 2024.